ABOUT THE EVENT
Date: Tuesday, December 8, 2026 12–1pm EST
Event Location: Virtual
This year tested many of the assumptions underpinning biotech forecasts. While analysts correctly identified several emerging trends, ongoing capital constraints, widening capability gaps and the growing importance of global development revealed a more complex reality than many expected. This webinar explores which predictions proved most accurate, where expectations diverged from market conditions and what those outcomes can teach leaders planning for 2027. Attendees will gain a clearer understanding of the forces that shaped 2026 and a practical framework for evaluating analyst guidance, operational readiness and investment risk.
This webinar aims to help attendees:
- Assess how capital market expectations compared with reality — examining where forecasts correctly anticipated improvement and where persistent backlog, prolonged funding pressures and late-stage capability challenges complicated the anticipated recovery.
- Understand how global drug development evolved during 2026 — including the impact of regulatory expectations, geopolitical uncertainty and the increasing importance of multi-jurisdiction development strategies.
- Evaluate how manufacturing and supply chain forecasts performed — exploring how geopolitical pressures, supply chain resilience efforts and technology transfer considerations influenced footprint and sourcing decisions across the industry.
Paul Bridges
President, Consulting | Parexel
Paul Bridges is President of Parexel’s Consulting organization, comprising Access Consulting, Regulatory Consulting, Strategic Compliance, Medical Communications – as well as Health Advances and The Medical Affairs Company (TMAC). In this role, he leads a global team of more than 2,100 colleagues including 80+ former regulators and HTA professionals. Parexel’s Consulting businesses support decision-making to minimize risk and maximize the probability of commercial success.
In his nearly two decades with Parexel, Paul’s experience includes serving as Vice President, European Account Management for Parexel Consulting as well as Senior Director of the consultancy’s regional UK Integrated Product Development (IPD) Consulting team. He joined the organization as a Principal Consultant providing strategic regulatory advice on all aspects of drug development with a special focus on Chemistry, Manufacturing and Controls (CMC).
Prior to Parexel, Paul was the European Director of Regulatory Affairs for INO Therapeutics and a pharmaceutical assessor for the UK Licensing Authority (MCA) with specific expertise in CMC. He has extensive knowledge of European licensing procedures from the perspective of both industry and regulatory authorities covering diverse therapeutic areas.
As part of his Ph.D. program, Paul studied the pulmonary delivery of drugs and has published work in this field. He is a member of the British Institute of Regulatory Affairs, the European Society of Regulatory Affairs, the Royal Pharmaceutical Society of Great Britain and the Royal Society of Medicine.
In his nearly two decades with Parexel, Paul’s experience includes serving as Vice President, European Account Management for Parexel Consulting as well as Senior Director of the consultancy’s regional UK Integrated Product Development (IPD) Consulting team. He joined the organization as a Principal Consultant providing strategic regulatory advice on all aspects of drug development with a special focus on Chemistry, Manufacturing and Controls (CMC).
Prior to Parexel, Paul was the European Director of Regulatory Affairs for INO Therapeutics and a pharmaceutical assessor for the UK Licensing Authority (MCA) with specific expertise in CMC. He has extensive knowledge of European licensing procedures from the perspective of both industry and regulatory authorities covering diverse therapeutic areas.
As part of his Ph.D. program, Paul studied the pulmonary delivery of drugs and has published work in this field. He is a member of the British Institute of Regulatory Affairs, the European Society of Regulatory Affairs, the Royal Pharmaceutical Society of Great Britain and the Royal Society of Medicine.
Brian Silver is a Partner in the Strategic Advisory Group at PJT Partners, based in New York.
Prior to joining PJT Partners, Mr. Silver was the Chief Financial Officer at TScan Therapeutics since 2021 and previously served on the board. Prior to joining TScan, Mr. Silver served as Freeline Therapeutics’ CFO and Head of Corporate Development from 2018 to 2021. In his two CFO roles, Mr. Silver led two Nasdaq IPOs and raised over $750 million through a combination of private and public equity financings, convertible and venture debt transactions as well as business development activity. Before joining Freeline, he was Partner and Head of Biotechnology in the healthcare practice at Perella Weinberg Partners. Prior to that, Mr. Silver was a Managing Director in Morgan Stanley’s healthcare investment banking group and a corporate associate at Sullivan & Cromwell.
Mr. Silver received a BA with honors from Harvard College and a JD with honors from the University of Chicago Law School.
Prior to joining PJT Partners, Mr. Silver was the Chief Financial Officer at TScan Therapeutics since 2021 and previously served on the board. Prior to joining TScan, Mr. Silver served as Freeline Therapeutics’ CFO and Head of Corporate Development from 2018 to 2021. In his two CFO roles, Mr. Silver led two Nasdaq IPOs and raised over $750 million through a combination of private and public equity financings, convertible and venture debt transactions as well as business development activity. Before joining Freeline, he was Partner and Head of Biotechnology in the healthcare practice at Perella Weinberg Partners. Prior to that, Mr. Silver was a Managing Director in Morgan Stanley’s healthcare investment banking group and a corporate associate at Sullivan & Cromwell.
Mr. Silver received a BA with honors from Harvard College and a JD with honors from the University of Chicago Law School.
Ali Pashazadeh
Founder and CEO | Treehill Partners
Ali Pashazadeh is Founder, Chairman and CEO of Treehill Partners, the global healthcare strategic and transaction advisory firm. He is an experienced healthcare investment banker, biotech CEO, and trained surgeon with significant expertise across the healthcare value chain.
Mr Pashazadeh’s healthcare investment banking career spans over 20 years, including at Goldman Sachs, UBS and Blackstone, where he advised companies and boards on large and complex strategic transactions around the globe.
Mr Pashazadeh has extensive hands-on operational experience, including as CEO in corporate turnaround situations and in the launch and growth phases of companies. He also has deep experience in the strategic development of therapeutic assets, across indications and development phases.
Mr Pashazadeh is a trained surgeon, who continues to be an active medical practitioner in the acute care setting having specialized as a trauma and reconstructive surgeon nearly 30 years ago.
Mr Pashazadeh’s healthcare investment banking career spans over 20 years, including at Goldman Sachs, UBS and Blackstone, where he advised companies and boards on large and complex strategic transactions around the globe.
Mr Pashazadeh has extensive hands-on operational experience, including as CEO in corporate turnaround situations and in the launch and growth phases of companies. He also has deep experience in the strategic development of therapeutic assets, across indications and development phases.
Mr Pashazadeh is a trained surgeon, who continues to be an active medical practitioner in the acute care setting having specialized as a trauma and reconstructive surgeon nearly 30 years ago.
